Abstract
Immunotoxins (ITs) are protein-based drugs combining a target-specific binding domain (usually derived from an antibody) and a cytotoxic domain to kill target cells. They are among the most promising new therapeutic tools to fight cancer, and several clinical trials have been completed with encouraging results. Although the targeted elimination of malignant cells is an elegant concept, there are numerous practical challenges that limit the clinical use of ITs, including inefficient cellular uptake, low cytotoxicity and off-target effects. Here we present some of the strategies that have been developed to improve the efficacy of ITs, particularly those involving the incorporation of functional peptide sequences into recombinant ITs to improve target binding, modify plasma half life and distribution, boost tumor penetration, enhance cellular uptake and increase cytotoxic efficiency.
Current Pharmaceutical Design
Title: Improved Immunotoxins with Novel Functional Elements
Volume: 15 Issue: 23
Author(s): C. Hetzel, C. Bachran, M K. Tur, H. Fuchs and M. Stocker
Affiliation:
Abstract: Immunotoxins (ITs) are protein-based drugs combining a target-specific binding domain (usually derived from an antibody) and a cytotoxic domain to kill target cells. They are among the most promising new therapeutic tools to fight cancer, and several clinical trials have been completed with encouraging results. Although the targeted elimination of malignant cells is an elegant concept, there are numerous practical challenges that limit the clinical use of ITs, including inefficient cellular uptake, low cytotoxicity and off-target effects. Here we present some of the strategies that have been developed to improve the efficacy of ITs, particularly those involving the incorporation of functional peptide sequences into recombinant ITs to improve target binding, modify plasma half life and distribution, boost tumor penetration, enhance cellular uptake and increase cytotoxic efficiency.
Export Options
About this article
Cite this article as:
Hetzel C., Bachran C., Tur K. M, Fuchs H. and Stocker M., Improved Immunotoxins with Novel Functional Elements, Current Pharmaceutical Design 2009; 15 (23) . https://dx.doi.org/10.2174/138161209788923930
DOI https://dx.doi.org/10.2174/138161209788923930 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Current Neuropharmacology Cationic Polymers and their Self-Assembly for Antibacterial Applications
Current Topics in Medicinal Chemistry Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Terpenes with Antitumor Activity: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Subject Index To Volume 7
Current Pharmaceutical Biotechnology Recent Advances in Biological Strategies for Targeted Drug Delivery
Cardiovascular & Hematological Disorders-Drug Targets Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Interaction of Endocannabinoid Receptors with Biological Membranes
Current Medicinal Chemistry Lipid based Nanocapsules: A Multitude of Biomedical Applications
Current Pharmaceutical Biotechnology Betulinic Acid as a Potent and Complex Antitumor Phytochemical: A Minireview
Anti-Cancer Agents in Medicinal Chemistry Temozolomide: An Update on Pharmacological Strategies to Increase its Antitumour Activity
Medicinal Chemistry Reviews - Online (Discontinued) The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy
Current Molecular Imaging (Discontinued) Mechanism of Action of Volatile Anesthetics: Involvement of Intracellular Calcium Signaling
Current Drug Targets - CNS & Neurological Disorders Regulation of Cell Migration and Invasion by Specific Modules of uPA: Mechanistic Insights and Specific Inhibitors
Current Drug Targets Retracted: miR-27b-3p Inhibits Invasion, Migration and Epithelial-mesenchymal Transition in Gastric Cancer by Targeting RUNX1 and Activation of the Hippo Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Bcl-2 Family Proteins as Therapeutic Targets
Current Pharmaceutical Design Cancer Stem Cell Markers in Nasopharyngeal Carcinoma and Its Relevance for Therapy
Current Traditional Medicine Tumor Protein p63/microRNA Network in Epithelial Cancer Cells
Current Genomics